L&L Biopharma Co., Ltd.

Primary Objective: To evaluate the antitumor efficacy of LB1410 in combination with lenvatinib (±LB4330). Secondary Objectives: (1) To evaluate the safety and tolerability of LB1410 in combination with lenvatinib (±LB4330). (2) To evaluate the progression-free survival (PFS), overall survival (OS), and disease control rate (DCR) of LB1410 in combination with lenvatinib (±LB4330). (3) To evaluate the immunogenicity (ADA) of LB1410. (4) To evaluate the pharmacokinetic characteristics of LB1410. Exploratory Objectives: (1) To explore the effects of TIM3 and PD-L1 expression on the efficacy of LB1410 in combination with lenvatinib (±LB4330). (2) To explore the pharmacodynamic characteristics of LB4330: peripheral blood-specific immune cytokines (including but not limited to IL-18 and IFN-γ), and their correlation with the efficacy of LB4330 in combination.

Primary objectives: 1. To evaluate the safety and tolerability of LB1410 combined with LB4330 in adult patients with advanced solid tumors. 2. To determine the maximum tolerated dose (MTD) and/or the recommended dose (RP2D) of LB1410 combined with LB4330 in the dose escalation phase. 3. To evaluate the anti-tumor efficacy of LB1410 combined with LB4330. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of LB1410 combined with LB4330 in patients with advanced solid tumors. 2. To evaluate the immunogenicity (ADA) of LB1410 combined with LB4330. 3. To evaluate the relationship between ADA and PK, safety and efficacy of LB1410 combined with LB4330. 4. To detect PD-L1, TIM3, and Claudin18.2 in tumor tissues collected at baseline (test items are subdivided by tumor type). Exploratory objectives: ? Pharmacodynamic or potential biological predictive markers of LB1410 combined with LB4330: lymphocyte subsets (including CD8+ T cells, CD4+ T cells, etc.), cytokines.